Baltimore, MD
Ketamine Therapy clinics in Baltimore
Baltimore has multiple clinics offering ketamine therapy, a fast growing segment for treatment resistant depression, PTSD, chronic pain, and anxiety. Maryland permits ketamine and Spravato REMS programs through DEA registered clinics; Johns Hopkins has a notable research footprint. Most Baltimore clinics deliver IV ketamine infusions in a monitored clinical setting, typically across a 6 session induction protocol, followed by maintenance infusions. Spravato (esketamine), the FDA approved nasal spray for treatment resistant depression, is available in Baltimore only at REMS certified clinics and is often covered by insurance when medical necessity is documented. Compounded ketamine lozenges and troches are also prescribed in Baltimore, sometimes through telehealth platforms like Mindbloom, Joyous, and Innerwell, subject to Ryan Haight Act and DEA special registration considerations. Local pricing in Baltimore sits in the standard range: single IV infusions run 500 to 900 dollars, a full 6 session protocol lands at 3,000 to 5,400, and Spravato copays depend on insurance coverage. A reputable Baltimore ketamine clinic will pair pharmacology with integration support, monitor vitals during infusion, and have a clear crisis and follow up plan.
Regulatory context
A note on Maryland's ketamine therapy rules.
Ketamine is a DEA Schedule III controlled substance, FDA-approved as a dissociative anesthetic and used off-label for treatment-resistant depression, PTSD, and chronic pain. The FDA approved esketamine (Spravato) in 2019 for treatment-resistant depression under a Risk Evaluation and Mitigation Strategy (REMS) program that requires in-office administration at certified sites. MDMA-assisted therapy remains Schedule I; the FDA issued a Complete Response Letter in August 2024 to Lykos Therapeutics on its MDMA new drug application. Psilocybin is Schedule I and holds FDA Breakthrough Therapy designation through sponsors such as Compass Pathways and Usona, but has not received FDA approval. Oregon Measure 109 (passed 2020, operational 2023) created a state psilocybin service center framework, and Colorado Proposition 122 (2022) authorized regulated healing centers.
-
Maryland Task Force on Responsible Use of Natural Psychedelic Substances (HB 548, 2024)
Established a task force to study regulated therapeutic access to psilocybin, DMT, and mescaline; report expected 2025. -
Scott Plotkin Act / Veterans Psychedelic Access (2023)
Allocated $1 million for veterans to access FDA-approved psychedelic clinical trials. -
Maryland Controlled Dangerous Substances Act
Mirrors federal scheduling.
Maryland enforces federal scheduling. The Maryland Board of Physicians oversees prescriber conduct. DEA enforcement on ketamine clinics focuses on diversion and Ryan Haight Act telehealth rules. Johns Hopkins runs one of the world's leading academic psychedelic research centers under federal IND authorization, giving Maryland substantial research infrastructure.